Drug assessment at a glance: A26-14[1]

Tirzepatide (type 2 diabetes mellitus in children and adolescents)

10 August 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-14. The G-BA decides on the added benefit.

Research question for the benefit assessment

Population	Children and adolescents aged 10 to ≤17 years with type 2 diabetes mellitus who have not achieved sufficient blood glucose control with their previous drug therapy in addition to diet and exercise
Intervention	tirzepatide
Comparator	Individualized treatment from a choice of ▪ metformin + basal insulin ▪ metformin + liraglutide or dulaglutide ▪ metformin + dapagliflozin or empagliflozin ▪ basal insulin + metformin + liraglutide or dulaglutide ▪ basal insulin + metformin + dapagliflozin or empagliflozin Escalation of insulin therapy: conventional therapy (CT) or intensified insulin therapy (ICT), in each case in combination with metformin and liraglutide or dulaglutide or dapagliflozin or empagliflozin
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects		Informative value of the effects	
Mortality	∅		–	
Morbidity	∅		–	
Symptoms	∅		–	
Health-related quality of life	∅		–	
Side effects	∅		–	
	∅	No (suitable) data	–	Not applicable
	↔	No advantage or disadvantage	★	Low
	↑ / ↓	Small advantage/disadvantage	★★	Moderate
	↑↑ / ↓↓	Moderate advantage/disadvantage	★★★	High
	↑↑↑ / ↓↓↓	Large advantage/disadvantage		

Overall: no advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No suitable data were available.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Tirzepatid (Diabetes mellitus Typ 2 bei Kindern und Jugendlichen); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 01.06.2026]. URL: https://doi.org/10.60584/A26-14.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Tirzepatid (Diabetes mellitus Typ 2 bei Kindern und Jugendlichen) [online]. 2026 [Accessed: 01.06.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1318/#nutzenbewertung.

English translations for this project are published at https://www.iqwig.de/en/projects/a26-14.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de